These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35368241)

  • 1. Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies.
    Nichols KK; Donnenfeld ED; Lau C; Syntosi A; Karpecki P; Hovanesian JA
    Clin Ophthalmol; 2022; 16():909-916. PubMed ID: 35368241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra
    Hovanesian JA; Nichols KK; Jackson M; Katz J; Chan A; Glassberg MB; Sloesen B; Korves C; Nguyen C; Syntosi A
    Clin Ophthalmol; 2021; 15():1041-1054. PubMed ID: 33727786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials.
    Holland EJ; Whitley WO; Sall K; Lane SS; Raychaudhuri A; Zhang SY; Shojaei A
    Curr Med Res Opin; 2016 Oct; 32(10):1759-1765. PubMed ID: 27388660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
    Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
    Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy.
    Godin MR; Gupta PK
    Clin Ophthalmol; 2017; 11():951-957. PubMed ID: 28579745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.
    Li JX; Tsai YY; Lai CT; Li YL; Wu YH; Chiang CC
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial.
    Nichols KK; Holland E; Toyos MM; Peace JH; Majmudar P; Raychaudhuri A; Hamdani M; Roy M; Shojaei A
    Clin Ophthalmol; 2018; 12():263-270. PubMed ID: 29440868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifitegrast for the treatment of dry eye disease in adults.
    Donnenfeld ED; Perry HD; Nattis AS; Rosenberg ED
    Expert Opin Pharmacother; 2017 Oct; 18(14):1517-1524. PubMed ID: 28841079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes of Lifitegrast 5% Ophthalmic Solution in the Treatment of Dry Eye Disease.
    Tong AY; Passi SF; Gupta PK
    Eye Contact Lens; 2020 Jan; 46 Suppl 1():S20-S24. PubMed ID: 30985492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease.
    White DE; Hendrix LH; Sun L; Tam I; Macsai M; Gibson AA
    J Manag Care Spec Pharm; 2023 Jan; 29(1):69-79. PubMed ID: 36030415
    [No Abstract]   [Full Text] [Related]  

  • 14. Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review.
    Atallah RT; Castanos MV; Najac R; Donnenfeld E
    Clin Ophthalmol; 2019; 13():1033-1037. PubMed ID: 31354236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye.
    White DE; Zhao Y; Ogundele A; Fulcher N; Acs A; Moore-Schiltz L; Karpecki PM
    Clin Ophthalmol; 2019; 13():2285-2292. PubMed ID: 31819353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifitegrast: a novel drug for patients with dry eye disease.
    Haber SL; Benson V; Buckway CJ; Gonzales JM; Romanet D; Scholes B
    Ther Adv Ophthalmol; 2019; 11():2515841419870366. PubMed ID: 31489402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease.
    McMullin D; Clark D; Cavanagh B; Karpecki P; Brady TC
    Clin Ophthalmol; 2021; 15():3889-3900. PubMed ID: 34588761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifitegrast: A novel drug for treatment of dry eye disease.
    Abidi A; Shukla P; Ahmad A
    J Pharmacol Pharmacother; 2016; 7(4):194-198. PubMed ID: 28163544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease.
    Semba CP; Gadek TR
    Clin Ophthalmol; 2016; 10():1083-94. PubMed ID: 27354762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of artificial tears on dynamic optical quality in patients with dry eye disease.
    Wei Z; Su Y; Su G; Baudouin C; Labbé A; Liang Q
    BMC Ophthalmol; 2022 Feb; 22(1):64. PubMed ID: 35144571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.